MarketInOut Stock Screener Log In | Sign Up
 

Incyte Corp

NASDAQ • Healthcare • Biotechnology • Quote as of 06/09/2026 14:00
Incyte Corp stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization20,106 mln
Float168 mln
Earnings Date08/04/2026

EPS

7.08
Strong

P / E

14.66
Fair value

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

-2.48
Borderline

1-Year Forecast

108
Fairly priced

Relative Strength

91 / 100
Top performer

Business Description

Incyte Corporation is a biopharmaceutical company founded in 1991 and based in Wilmington, Delaware, that discovers, develops, and sells treatments for cancers and other serious diseases across the United States, Europe, Canada, and Japan. The company markets several approved medicines targeting blood cancers, lymphomas, and graft-versus-host disease, while also advancing a broad pipeline of experimental treatments for conditions ranging from ovarian cancer to rare inflammatory diseases. Incyte works alongside partners such as Novartis, Lilly, and Syndax, and distributes its products through specialty pharmacies, hospital pharmacies, and distributors.

Key Fundamentals

EPS7.08
P/E14.66
ROE30.75
RPS26.42
ROIC39.89
ROA22.23
Interest Cover621
EBITDA, mln1,871
EV / EBITDA8.27
EV / EBIT8.71
Revenue, mln5,361
EV / Revenue2.89

Financial Strength

Altman Z-Score9.06
Piotroski F-Score 7 / 9
Beneish M-Score-2.48
Price to Intrinsic Value1.70
Price to Lynch Fair Value0.70
Price to Graham Number1.50
1-Year Target Price108
Shiller PE Ratio56.22
Short Ratio7.59
Short % of Float9.52

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 12.45% 97 / 100   
1 Month 5.24% 84 / 100   
2 Months 5.76% 66 / 100   
6 Months 1.17% 46 / 100   
1 Year 50.82% 84 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us